Professor Rachel Yehuda from the Icahn School of Medicine at Mount Sinai describes psychedelics as “heart openers” and Dr. Liliana Galindo from the University of Cambridge likens their action to a surgeon’s scalpel, but each agree that psychedelic-assisted therapy may offer lasting relief to people struggling with a wide range of mental health problems.
Both join Lancet editors Jonathan and Matt to discuss the burgeoning field of psychedelic-assisted therapy. LSD, MDMA, 5-MeO-DMT, psilocybin, anxiety, depression, eating disorders, substance-use disorders, post-traumatic stress disorder; potentially-pivotal phase 3 trial data are maturing amid growing interest from regulators and investors, but many practical questions remain before the patients most in need may benefit from this psychedelic renaissance.
---------------------------------
The Lancet Pulse is part of the Lancet Group podcast offering.
Editorial team: Chloe Wilson, Ben Abbott, Matthew Gilbert, and Jonathan Pimm
Podcast editing and production: Matteo Simonetti
Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.
Find the best science for better lives at https://www.thelancet.com
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
The Lancet Pulse is part of the Lancet Group podcast offering.
Editorial team: Chloe Wilson, Ben Abbott, Matthew Gilbert, and Jonathan Pimm
Podcast editing and production: Matteo Simonetti
Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.
Find the best science for better lives at https://www.thelancet.com
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
